S&P 500   4,269.80 (-0.10%)
DOW   33,859.97 (-0.35%)
QQQ   328.75 (+0.08%)
AAPL   173.88 (-0.38%)
MSFT   290.53 (-0.27%)
META   174.50 (-0.20%)
GOOGL   120.03 (+0.40%)
AMZN   142.21 (+0.08%)
TSLA   911.05 (-0.10%)
NVDA   186.76 (+1.86%)
NIO   19.84 (-1.20%)
BABA   90.41 (+0.71%)
AMD   100.33 (+2.10%)
MU   62.82 (+1.95%)
T   18.41 (-0.05%)
CGC   3.78 (-6.90%)
F   16.00 (-0.19%)
GE   79.05 (-1.09%)
DIS   122.23 (-0.47%)
AMC   20.01 (-6.32%)
PYPL   98.59 (-0.83%)
PFE   48.48 (-1.60%)
NFLX   244.66 (+1.46%)
S&P 500   4,269.80 (-0.10%)
DOW   33,859.97 (-0.35%)
QQQ   328.75 (+0.08%)
AAPL   173.88 (-0.38%)
MSFT   290.53 (-0.27%)
META   174.50 (-0.20%)
GOOGL   120.03 (+0.40%)
AMZN   142.21 (+0.08%)
TSLA   911.05 (-0.10%)
NVDA   186.76 (+1.86%)
NIO   19.84 (-1.20%)
BABA   90.41 (+0.71%)
AMD   100.33 (+2.10%)
MU   62.82 (+1.95%)
T   18.41 (-0.05%)
CGC   3.78 (-6.90%)
F   16.00 (-0.19%)
GE   79.05 (-1.09%)
DIS   122.23 (-0.47%)
AMC   20.01 (-6.32%)
PYPL   98.59 (-0.83%)
PFE   48.48 (-1.60%)
NFLX   244.66 (+1.46%)
S&P 500   4,269.80 (-0.10%)
DOW   33,859.97 (-0.35%)
QQQ   328.75 (+0.08%)
AAPL   173.88 (-0.38%)
MSFT   290.53 (-0.27%)
META   174.50 (-0.20%)
GOOGL   120.03 (+0.40%)
AMZN   142.21 (+0.08%)
TSLA   911.05 (-0.10%)
NVDA   186.76 (+1.86%)
NIO   19.84 (-1.20%)
BABA   90.41 (+0.71%)
AMD   100.33 (+2.10%)
MU   62.82 (+1.95%)
T   18.41 (-0.05%)
CGC   3.78 (-6.90%)
F   16.00 (-0.19%)
GE   79.05 (-1.09%)
DIS   122.23 (-0.47%)
AMC   20.01 (-6.32%)
PYPL   98.59 (-0.83%)
PFE   48.48 (-1.60%)
NFLX   244.66 (+1.46%)
S&P 500   4,269.80 (-0.10%)
DOW   33,859.97 (-0.35%)
QQQ   328.75 (+0.08%)
AAPL   173.88 (-0.38%)
MSFT   290.53 (-0.27%)
META   174.50 (-0.20%)
GOOGL   120.03 (+0.40%)
AMZN   142.21 (+0.08%)
TSLA   911.05 (-0.10%)
NVDA   186.76 (+1.86%)
NIO   19.84 (-1.20%)
BABA   90.41 (+0.71%)
AMD   100.33 (+2.10%)
MU   62.82 (+1.95%)
T   18.41 (-0.05%)
CGC   3.78 (-6.90%)
F   16.00 (-0.19%)
GE   79.05 (-1.09%)
DIS   122.23 (-0.47%)
AMC   20.01 (-6.32%)
PYPL   98.59 (-0.83%)
PFE   48.48 (-1.60%)
NFLX   244.66 (+1.46%)
OTCMKTS:ADDXF

Addex Therapeutics - ADDXF Stock Forecast, Price & News

$0.99
0.00 (0.00%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.99
$0.99
50-Day Range
$0.99
$0.99
52-Week Range
$0.99
$0.99
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ADDXF stock logo

About Addex Therapeutics (OTCMKTS:ADDXF) Stock

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Receive ADDXF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADDXF Stock News Headlines

See More Headlines
Receive ADDXF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADDXF Company Calendar

Today
8/18/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ADDXF
CIK
N/A
Fax
N/A
Employees
26
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.45

Key Executives

  • Mr. Timothy Mark Dyer (Age 54)
    Co-Founder, CEO & Director
  • Dr. Roger G. Mills M.D. (Age 65)
    Chief Medical Officer & Director
  • Mr. Lénaic Teyssédou (Age 36)
    Head of Fin.
  • Dr. Jean-Philippe Rocher Ph.D. (Age 63)
    Head of Discovery - Chemistry
  • Dr. Robert Lutjens (Age 54)
    Head of Discovery - Biology
  • Dr. Mikhail Kalinichev Ph.D. (Age 54)
    Head of Translational Science
  • Dr. Werner Henrichi Ph.D. (Age 79)
    Consultant













ADDXF Stock - Frequently Asked Questions

How have ADDXF shares performed in 2022?

Addex Therapeutics' stock was trading at $1.56 at the beginning of 2022. Since then, ADDXF stock has decreased by 36.5% and is now trading at $0.99.
View the best growth stocks for 2022 here
.

What is Addex Therapeutics' stock symbol?

Addex Therapeutics trades on the OTCMKTS under the ticker symbol "ADDXF."

How do I buy shares of Addex Therapeutics?

Shares of ADDXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Addex Therapeutics' stock price today?

One share of ADDXF stock can currently be purchased for approximately $0.99.

How can I contact Addex Therapeutics?

The official website for the company is www.addextherapeutics.com. The company can be reached via phone at 41 22 884 1555.

This page (OTCMKTS:ADDXF) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.